NEW YORK (GenomeWeb News) – Enigma Diagnostics this week said that it has received a Biomedical Catalyst grant from the UK government to support further development of multiplexed PCR assays using the firm's ResonSense probing technology. It didn't disclose the amount of funding it received under the grant. The firm said it plans to use the money to demonstrate ResonSense can detect and differentiate "many more target sequences in a single closed-tube assay than conventional PCR chemistries."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.